Special Interest Group (SIG)
Jonathan Lee, PhD
Senior Research Advisor
Eli Lilly
The phenotypic drug discovery (PDD) SIG will serve as a discussion forum for the global research community to share/discuss/debate topics related to PDD research. Participants will share their experiences, perceptions, and thoughts on the advantages/disadvantages of PDD and whether/how PDD complements targeted drug discovery (TDD) strategies. Related topics such as target identification/validation, chemical diversity, chemical genomics, chemo-informatics, poly-pharmacology, translational pharmacology, biological model systems and patient tailoring are also in scope.
Senior Research Advisor
Eli Lilly
Phenotypic Screening: Why, When and How
Sunday, February 4
8:00 AM – 3:15 PM
Phenotypic Drug Discovery Special Interest Group (SIG)
Tuesday, February 6
8:00 AM – 9:15 AM
The asset you are trying to access is locked. Please enter your access key to unlock.